Consumer Health Cancer / Oncology

BioNTech and OncoC4 to Co-Develop and Commercialize Novel Checkpoint Antibody for Solid Tumor Treatment

 BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”), a clinical-stage biopharmaceutical company dedicated...

 March 20, 2023 | News

Etana has secured financing from Deg, East Ventures and other global investors

 Etana is committed to build production capacity for mammalian cell for monoclonal antibodies drug substance to ensure high local content production a...

 March 20, 2023 | News

Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003

ADC drugs have the advantages of highly specific targeting of antibody and anti cancer activity of cytotoxin. ADC shave developed rapidly as tumor therapeu...

 March 16, 2023 | News

Pfizer Invests $43 Billion to Battle Cancer

Pfizer to acquire Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion Proposed combination enhances Pfiz...

 March 14, 2023 | News

Porton Advanced and Bennu Biotherapeutics Partner to Develop Cell Therapy for Solid Tumors

As an end-to-end gene and cell therapy service CDMO, Porton Advanced provides comprehensive solutions covering plasmids, cell therapy, gene therapy, oncoly...

 March 13, 2023 | News

TransCure bioServices delivers CDX mouse models to advance AML preclinical studies

TransCure bioServices has developed cell line-derived xenograft (CDX) mouse models that will change how researchers tackle the preclinical studies of cance...

 March 07, 2023 | News

Prenetics Forms Advisory Board for Precision Oncology Strategy

Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to announce the formation of a new Prenetics Scientific Adviso...

 March 02, 2023 | News

Debiopharm Acquires Global Rights for Novo Nordisk's USP1 Inhibitor Development.

Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow's standard-of-care treatments to cure can...

 March 02, 2023 | News

JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma

Primary hepatic cancer is a common malignant tumor of the digestive system worldwide, with high malignancy and hepatic prognosis. As the most common pathol...

 March 01, 2023 | News

Gene Solutions' Latest Update: Promising Multi-Cancer Early Detection in Southeast Asia

Circulating tumor DNA, or cell-free tumor DNA (ctDNA) assay is based on detecting the appearance of ctDNA in blood. This method is sometimes called Liquid ...

 March 01, 2023 | News

Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Ovarian Cancer

The clinical trial to be conducted by Peter Mac will be the first time a CAR-T cell therapy product containing the genetic modifications incorporated into ...

 February 27, 2023 | News

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

Prior to this approval from the US FDA, Biosyngen's BRG01 was granted IND by China CDE on December 14th, 2022. In addition, China CDE has acknowledged...

 February 18, 2023 | News

Eurofins Discovery Collaborating with Invasight on Cancer Therapies

Invasight is teaming with Eurofins Discovery's DiscoveryOne™, an integrated drug discovery platform that provides expert comprehensive support t...

 February 15, 2023 | News

Boan Biotech's Investigational Anti-CD25 Antibody BA1106 Administered for First Patient in Phase I Clinical Trial

BA1106 is the first investigational anti-CD25 antibody to start clinical trials in China for treating solid tumors. Focusing on key therapeutic a...

 February 13, 2023 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close